tiprankstipranks
Cybin’s Phase 3 Trials and Financial Update
Company Announcements

Cybin’s Phase 3 Trials and Financial Update

Story Highlights

Cybin (TSE:CYBN) has released an update.

Don't Miss our Black Friday Offers:

Cybin has launched a pivotal Phase 3 program named PARADIGM to evaluate CYB003 as a treatment for Major Depressive Disorder, involving multiple studies across the U.S. and Europe. The company also reported a strong cash position with C$154.3 million as of September 30, 2024, highlighting its financial readiness for these trials.

For further insights into TSE:CYBN stock, check out TipRanks’ Stock Analysis page.

Related Articles
TheFlyRising High: Numinus Wellness to sell five Utah clinics for $3.53M
TipRanks Canadian Auto-Generated NewsdeskCybin’s CYB003 Shows Promising Results for Depression
TheFlyCybin: CYB003 data demonstres ‘breakthrough 12-month efficacy’ in MDD treatment
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App